Oxidative stress as a possible mechanism of statin-induced myopathy
dc.contributor.author | Ahmadi, Y | |
dc.contributor.author | Ghorbanihaghjo, A | |
dc.contributor.author | Naghi-Zadeh, M | |
dc.contributor.author | Yagin, NL | |
dc.date.accessioned | 2018-08-26T07:11:27Z | |
dc.date.available | 2018-08-26T07:11:27Z | |
dc.date.issued | 2018 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/44317 | |
dc.description.abstract | Statins, inhibitors of hydroxy methyl glutaryl coenzyme-A (HMG-CoA) reductase, are the most widely used drugs for treating hypercholesterolemia. However, statins can cause disabling myopathy as their main adverse effect. Several molecular mechanisms underlie the statin-induced myopathy including the decrease in the levels of essential mevalonate and cholesterol derivatives. This review discusses a further mechanism involving the loss of other anti-oxidant defenses besides ubiquinone (Co-Q) in skeletal muscles which produce a significant amount of reactive oxygen species (ROS). Therefore, to maintain their function, skeletal muscles need a high level of anti-oxidants. | |
dc.language.iso | English | |
dc.relation.ispartof | INFLAMMOPHARMACOLOGY | |
dc.subject | Cholesterol | |
dc.subject | Myopathy | |
dc.subject | Oxidative stress | |
dc.subject | Statins | |
dc.subject | Ubiquinone | |
dc.title | Oxidative stress as a possible mechanism of statin-induced myopathy | |
dc.type | Review | |
dc.citation.volume | 26 | |
dc.citation.issue | 3 | |
dc.citation.spage | 667 | |
dc.citation.epage | 674 | |
dc.citation.index | Web of science | |
dc.identifier.DOI | https://doi.org/10.1007/s10787-018-0469-x |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |